Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)

Kwang Dong Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Other Revenue	-	-	-	-	-0	-
Revenue	1,605,836	1,640,719	1,514,454	1,431,545	1,338,182	1,243,770
Revenue Growth (YoY)	2.28%	8.34%	5.79%	6.98%	7.59%	0.45%
Cost of Revenue	1,322,269	1,343,737	1,216,563	1,151,550	1,065,870	987,672
Gross Profit	283,567	296,982	297,891	279,995	272,312	256,098
Selling, General & Admin	247,066	246,225	233,331	225,167	213,458	196,462
Research & Development	10,116	10,128	15,275	9,678	8,322	5,957
Other Operating Expenses	1,447	2,059	1,989	1,391	1,589	2,857
Operating Expenses	267,191	266,885	255,821	241,751	227,376	209,507
Operating Income	16,376	30,097	42,070	38,244	44,936	46,591
Interest Expense	-10,584	-10,274	-6,904	-3,735	-2,544	-2,539
Interest & Investment Income	5,448	6,319	5,399	2,844	2,415	2,850
Earnings From Equity Investments	-3,347	767.76	-429.82	-435.51	-112.22	-62.65
Currency Exchange Gain (Loss)	3,872	3,159	-384.81	6.49	693.27	-800.07
Other Non Operating Income (Expenses)	-985.25	-1,169	-179.12	1,132	-865.71	932.94
EBT Excluding Unusual Items	10,780	28,900	39,571	38,056	44,522	46,972
Gain (Loss) on Sale of Investments	16,115	25,399	9,412	-1,932	-10,232	17,536
Gain (Loss) on Sale of Assets	10,034	3,026	-1,964	166.52	38.87	1,178
Asset Writedown	-	-	-	-	-	-2,735
Pretax Income	36,928	57,325	49,019	36,291	34,329	62,951
Income Tax Expense	9,382	15,480	9,648	9,590	8,788	17,349
Earnings From Continuing Operations	27,546	41,845	39,372	26,701	25,541	45,602
Minority Interest in Earnings	-1,517	-1,364	-2,406	-2,527	-1,522	-232.19
Net Income	26,029	40,481	36,966	24,174	24,019	45,370
Net Income to Common	26,029	40,481	36,966	24,174	24,019	45,370
Net Income Growth	-36.70%	9.51%	52.91%	0.65%	-47.06%	96.76%
Shares Outstanding (Basic)	40	40	40	41	41	41
Shares Outstanding (Diluted)	40	40	40	41	41	41
Shares Change (YoY)	-0.88%	-1.10%	-1.48%	-0.11%	1.48%	2.24%
EPS (Basic)	652.88	1011.34	913.39	588.45	584.68	1119.49
EPS (Diluted)	652.53	1011.00	913.00	588.00	584.33	1119.00
EPS Growth	-36.12%	10.73%	55.27%	0.63%	-47.78%	92.36%
Free Cash Flow	-49,848	-87,883	-46,515	37,439	31,145	17,566
Free Cash Flow Per Share	-1250.34	-2195.59	-1149.35	911.36	757.27	433.44
Dividend Per Share	-	-	-	100.000	100.000	100.000
Dividend Growth	-	-	-	-	-	25.00%
Gross Margin	17.66%	18.10%	19.67%	19.56%	20.35%	20.59%
Operating Margin	1.02%	1.83%	2.78%	2.67%	3.36%	3.75%
Profit Margin	1.62%	2.47%	2.44%	1.69%	1.80%	3.65%
Free Cash Flow Margin	-3.10%	-5.36%	-3.07%	2.61%	2.33%	1.41%
EBITDA	31,223	44,629	54,974	52,262	59,045	66,299
EBITDA Margin	1.94%	2.72%	3.63%	3.65%	4.41%	5.33%
D&A For EBITDA	14,848	14,532	12,904	14,017	14,110	19,709
EBIT	16,376	30,097	42,070	38,244	44,936	46,591
EBIT Margin	1.02%	1.83%	2.78%	2.67%	3.36%	3.75%
Effective Tax Rate	25.41%	27.00%	19.68%	26.43%	25.60%	27.56%
Advertising Expenses	-	45,513	46,186	42,214	40,464	37,872

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.